Laurence Malbert-Colas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Laurence Malbert-Colas has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Borivoj Vojtesek
Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
1 shared publication - Chrysoula Daskalogianni
Institut de Recherche Saint Louis, Unité Mixte de Recherches 1342, Université Paris Cité, Hôpital St. Louis
1 shared publication - Daniel Öhlund
Department of Diagnostics and Intervention, Umeå University
1 shared publication Josef Kucera
Research Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute
1 shared publication- Justine Habault
Institut de Recherche Saint Louis, Unité Mixte de Recherches 1342, Université Paris Cité, Hôpital St. Louis
1 shared publication Lenka Hernychová
Research Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute
1 shared publication
Latest Publications
- Open Access
- 23 June 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (26)
MDM2 suppresses c-Myc synthesis by binding to the 5’ mRNA translation regulatory sequence
The p53 tumor suppressor and the c-Myc oncogene are among the most frequently deregulated genes in human cancers, yet the molecular cross talk between these pathways remains poorly understood. MDM2 is a key negative regulator of p53 and a target for emerging cancer therapies designed to activate p53. Likewise, targeting c-Myc is a long-standing but challenging goal in cancer therapy. Here, we report that the small MDM2-binding drug Milademetan promotes an interaction between MDM2 and the 5’ untranslated region of the c-Myc mRNA, causing a suppression of c-Myc mRNA translation without affecting c-Myc RNA levels. The interaction also occurs under nonproliferative conditions in the absence of drug. Milademetan-mediated c-Myc depletion is accompanied by the induction of apoptosis and suppression of cell proliferation and prevents tumor growth, independently of p53 status. These findings reveal an unexpected mechanism by which MDM2 coordinates two of the most frequently altered pathways in cancer and provide a rationale for targeting c-Myc-driven tumors, including those lacking functional p53, through MDM2 modulators.
- 23 June 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (26)
Open AccessMDM2 suppresses c-Myc synthesis by binding to the 5’ mRNA translation regulatory sequence
The p53 tumor suppressor and the c-Myc oncogene are among the most frequently deregulated genes in human cancers, yet the molecular cross talk between these pathways remains poorly understood. MDM2 is a key negative regulator of p53 and a target for emerging cancer therapies designed to activate p53. Likewise, targeting c-Myc is a long-standing but challenging goal in cancer therapy. Here, we report that the small MDM2-binding drug Milademetan promotes an interaction between MDM2 and the 5’ untranslated region of the c-Myc mRNA, causing a suppression of c-Myc mRNA translation without affecting c-Myc RNA levels. The interaction also occurs under nonproliferative conditions in the absence of drug. Milademetan-mediated c-Myc depletion is accompanied by the induction of apoptosis and suppression of cell proliferation and prevents tumor growth, independently of p53 status. These findings reveal an unexpected mechanism by which MDM2 coordinates two of the most frequently altered pathways in cancer and provide a rationale for targeting c-Myc-driven tumors, including those lacking functional p53, through MDM2 modulators.